TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

What's Going On With Royalty Pharma Stock Wednesday?

Benzinga Logo Benzinga • •By Vandana Singh
What's Going On With Royalty Pharma Stock Wednesday?

Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slightly on Wednesday. The company also recently acquired royalty interests in Nuvalent's cancer drugs.

Insights
RPRX   positive

Acquisition of full royalty ownership on Evrysdi, a successful drug with strong sales growth trajectory ($1.9B to $2.9B by 2030), plus recent Nuvalent royalty deal demonstrates strategic portfolio expansion and revenue diversification.